Matrix metalloproteinase-2 (MMP-2) (MMP-2)

Matrix metalloproteinase-2 (MMP-2), historically known as 72 kDa type IV collagenase or Gelatinase A, is a zinc-dependent endopeptidase essential for the degradation of extracellular matrix (ECM) components. It specifically cleaves type IV collagen, the primary structural element of basement membranes, along with gelatin, elastin, and various non-matrix proteins [UniProt P08253]. Under physiological conditions, MMP-2 facilitates tissue remodeling, wound healing, and angiogenesis; however, its overexpression is linked to pathological states such as cancer metastasis and cardiovascular disease [PubMed: 28614108]. In oncology, MMP-2 promotes tumor invasion by degrading the basement membrane, allowing cancer cells to enter the vasculature and colonize distant sites [PubMed: 12115117]. While numerous broad-spectrum MMP inhibitors like Marimastat were developed to target this enzyme, they largely failed in clinical trials due to dose-limiting musculoskeletal toxicity and a lack of isoform specificity [PubMed: 11894164]. Current research focuses on developing highly selective inhibitors or antibody-based therapies to mitigate these safety concerns and improve therapeutic outcomes in chronic inflammatory and malignant diseases.

Other names

72 kDa type IV collagenaseGelatinase A72 kDa gelatinaseTBE-1PEXCLG4AMMP2

Inhibition of the catalytic zinc-dependent active site to prevent the degradation of extracellular matrix components, particularly type IV collagen, thereby inhibiting tumor invasion and angiogenesis.